Cargando…
Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities
Due to the speed, efficiency, relative risk, and lower costs compared to traditional drug discovery, the prioritization of candidate drugs for repurposing against cancers of interest has attracted the attention of experts in recent years. Herein, we present a powerful computational approach, termed...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6763777/ https://www.ncbi.nlm.nih.gov/pubmed/31408580 http://dx.doi.org/10.1002/1878-0261.12564 |
_version_ | 1783454270943657984 |
---|---|
author | Di, Jieyi Zheng, Baotong Kong, Qingfei Jiang, Ying Liu, Siyao Yang, Yang Han, Xudong Sheng, Yuqi Zhang, Yunpeng Cheng, Liang Han, Junwei |
author_facet | Di, Jieyi Zheng, Baotong Kong, Qingfei Jiang, Ying Liu, Siyao Yang, Yang Han, Xudong Sheng, Yuqi Zhang, Yunpeng Cheng, Liang Han, Junwei |
author_sort | Di, Jieyi |
collection | PubMed |
description | Due to the speed, efficiency, relative risk, and lower costs compared to traditional drug discovery, the prioritization of candidate drugs for repurposing against cancers of interest has attracted the attention of experts in recent years. Herein, we present a powerful computational approach, termed prioritization of candidate drugs (PriorCD), for the prioritization of candidate cancer drugs based on a global network propagation algorithm and a drug–drug functional similarity network constructed by integrating pathway activity profiles and drug activity profiles. This provides a new approach to drug repurposing by first considering the drug functional similarities at the pathway level. The performance of PriorCD in drug repurposing was evaluated by using drug datasets of breast cancer and ovarian cancer. Cross‐validation tests on the drugs approved for the treatment of these cancers indicated that our approach can achieve area under receiver‐operating characteristic curve (AUROC) values greater than 0.82. Furthermore, literature searches validated our results, and comparison with other classical gene‐based repurposing methods indicated that our pathway‐level PriorCD is comparatively more effective at prioritizing candidate drugs with similar therapeutic effects. We hope that our study will be of benefit to the field of drug discovery. In order to expand the usage of PriorCD, a freely available R‐based package, PriorCD, has been developed to prioritize candidate anticancer drugs for drug repurposing. |
format | Online Article Text |
id | pubmed-6763777 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-67637772019-10-01 Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities Di, Jieyi Zheng, Baotong Kong, Qingfei Jiang, Ying Liu, Siyao Yang, Yang Han, Xudong Sheng, Yuqi Zhang, Yunpeng Cheng, Liang Han, Junwei Mol Oncol Research Articles Due to the speed, efficiency, relative risk, and lower costs compared to traditional drug discovery, the prioritization of candidate drugs for repurposing against cancers of interest has attracted the attention of experts in recent years. Herein, we present a powerful computational approach, termed prioritization of candidate drugs (PriorCD), for the prioritization of candidate cancer drugs based on a global network propagation algorithm and a drug–drug functional similarity network constructed by integrating pathway activity profiles and drug activity profiles. This provides a new approach to drug repurposing by first considering the drug functional similarities at the pathway level. The performance of PriorCD in drug repurposing was evaluated by using drug datasets of breast cancer and ovarian cancer. Cross‐validation tests on the drugs approved for the treatment of these cancers indicated that our approach can achieve area under receiver‐operating characteristic curve (AUROC) values greater than 0.82. Furthermore, literature searches validated our results, and comparison with other classical gene‐based repurposing methods indicated that our pathway‐level PriorCD is comparatively more effective at prioritizing candidate drugs with similar therapeutic effects. We hope that our study will be of benefit to the field of drug discovery. In order to expand the usage of PriorCD, a freely available R‐based package, PriorCD, has been developed to prioritize candidate anticancer drugs for drug repurposing. John Wiley and Sons Inc. 2019-08-21 2019-10 /pmc/articles/PMC6763777/ /pubmed/31408580 http://dx.doi.org/10.1002/1878-0261.12564 Text en © 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Di, Jieyi Zheng, Baotong Kong, Qingfei Jiang, Ying Liu, Siyao Yang, Yang Han, Xudong Sheng, Yuqi Zhang, Yunpeng Cheng, Liang Han, Junwei Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities |
title | Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities |
title_full | Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities |
title_fullStr | Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities |
title_full_unstemmed | Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities |
title_short | Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities |
title_sort | prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6763777/ https://www.ncbi.nlm.nih.gov/pubmed/31408580 http://dx.doi.org/10.1002/1878-0261.12564 |
work_keys_str_mv | AT dijieyi prioritizationofcandidatecancerdrugsbasedonadrugfunctionalsimilaritynetworkconstructedbyintegratingpathwayactivitiesanddrugactivities AT zhengbaotong prioritizationofcandidatecancerdrugsbasedonadrugfunctionalsimilaritynetworkconstructedbyintegratingpathwayactivitiesanddrugactivities AT kongqingfei prioritizationofcandidatecancerdrugsbasedonadrugfunctionalsimilaritynetworkconstructedbyintegratingpathwayactivitiesanddrugactivities AT jiangying prioritizationofcandidatecancerdrugsbasedonadrugfunctionalsimilaritynetworkconstructedbyintegratingpathwayactivitiesanddrugactivities AT liusiyao prioritizationofcandidatecancerdrugsbasedonadrugfunctionalsimilaritynetworkconstructedbyintegratingpathwayactivitiesanddrugactivities AT yangyang prioritizationofcandidatecancerdrugsbasedonadrugfunctionalsimilaritynetworkconstructedbyintegratingpathwayactivitiesanddrugactivities AT hanxudong prioritizationofcandidatecancerdrugsbasedonadrugfunctionalsimilaritynetworkconstructedbyintegratingpathwayactivitiesanddrugactivities AT shengyuqi prioritizationofcandidatecancerdrugsbasedonadrugfunctionalsimilaritynetworkconstructedbyintegratingpathwayactivitiesanddrugactivities AT zhangyunpeng prioritizationofcandidatecancerdrugsbasedonadrugfunctionalsimilaritynetworkconstructedbyintegratingpathwayactivitiesanddrugactivities AT chengliang prioritizationofcandidatecancerdrugsbasedonadrugfunctionalsimilaritynetworkconstructedbyintegratingpathwayactivitiesanddrugactivities AT hanjunwei prioritizationofcandidatecancerdrugsbasedonadrugfunctionalsimilaritynetworkconstructedbyintegratingpathwayactivitiesanddrugactivities |